Rhinomed (ASX:RNO), a company working on wearable nasal and respiratory technology, says it has received purchase orders and begun supplying NSW Health Pathology with an initial one million Rhinoswabs.
The company said it has commenced deliveries with these initial orders being fulfilled over the coming weeks. It said it is now scaling up its manufacturing facilities to respond to growing domestic and international demand for this technology.
Rhinomed said its Rhinoswab technology improves the sample collection process.
"As previously disclosed the Rhinoswab is substantially more comfortable and easier to use than the standard nasal swab, captures a larger sample, can accelerate the sample collection process and significantly reduce queues and waiting times," said the company in a statement.
Rhinoswab works with existing PCR (polymerase chain reaction) pathology workflows and equipment and has equivalent cost and quality to the US and European standard of care nasopharyngeal swabs.
"Interim results from a recent comparison study (n= 204) being completed at CWZ and Radboud University Medical Center, a leading teaching hospital in Nijmegen in the Netherlands are in line with the previously announced user study results and showed participants' strong preference for the Rhinoswab when compared to the traditional nasal swab," said Rhinomed.
Rhinomed CEO Michael Johnson said, “We are thrilled to receive this support for this Australian innovation. The Rhinoswab can make a meaningful impact on the SARS-CoV-2 testing process and enable more people to be tested quickly and easily. With approximately 2 billion SARS-CoV-2 tests having been carried out globally over the last 18 months (close to 26 million* in Australia alone), there is a major opportunity for Rhinoswab to radically improve the testing process, clinical outcomes and user experience.”